Engineered Tumor-Specific T-Cells May Help Relapsed Hodgkin Lymphoma Patients

A recent study found that Hodgkin lymphoma patients with active disease achieved clinical responses with tumor-specific T-cells that were genetically modified to be rendered resistant to transforming growth factor beta, a cytokine expressed by most human cancers.

Source: CancerNetwork - January 24, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Hematologic Malignancies Hodgkin Lymphoma News Source Type: news